Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Strattera Is First ADHD Agent With Adult Indication, Full-Scale Launch

Executive Summary

Lilly's Strattera will be the first ADHD therapy to have a traditional full-scale pharmaceutical launch

You may also be interested in...



Pfizer Lyrica Launch Awaits Controlled Substance Scheduling

Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration

Pfizer Lyrica Launch Awaits Controlled Substance Scheduling

Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration

Quarterly Earnings Calls, In Brief

Novartis Prexige advisory committee?: Novartis Prexige gastrointestinal and cardiovascular safety study on COX-2 inhibitor could be subject of FDA advisory committee meeting next year, Global Pharma Development Head Joerg Reinhardt, PhD, tells analysts July 21. Final results from 18,000-patient TARGET study will be available in early 2004 (1"The Pink Sheet" Nov. 21, 2001, p. 32). FDA's arthritis committee reviewed similar outcomes studies for Pfizer's Celebrex and Merck's Vioxx in 2001 (2"The Pink Sheet" Feb. 12, 2001, p. 6). Novartis has not yet heard whether the Prexige (lumiracoxib) NDA will be the subject of committee review. Prexige's user fee deadline is in late September...

Related Content

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel